AXIOS™ for Gallbladder Drainage as an Alternative to Percutaneous Drainage IDE

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-10

Study Completion Date

2021-12-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the safety and effectiveness of the AXIOS™ Stent with Electrocautery Enhanced Delivery System in the management of symptoms of acute cholecystitis as an alternative to percutaneous gallbladder drainage.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AXIOS Stent With Electrocautery Enhanced Delivery System

NCT02146352

Pancreatic Pseudocyst(s)

COMPLETED NA

Hot AXIOS™ for Bile Duct Drainage in Malignant Stenosis

NCT06750146

Malignant Biliary Stenosis

SUSPENDED NA

AXIOS Stent & Delivery System Study

NCT01419769

Pancreatic Pseudocyst(s)

COMPLETED NA

AXIOS Lumen Apposing Metal Stent for Walled Off Necrosis Drainage IDE Study

NCT03525808

Walled Off Pancreatic Necrosis

COMPLETED NA

A First-in-Man Clinical Trial to Evaluate the Safety and Feasibility of ICS-Elpis in Patients With Iliac Artery Stenosis or Occlusion Lesions

NCT07290101

Iliac Artery Stenosis Iliac Artery Occlusion

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a prospective, single arm, multi center trial. Treatment of up to 30 patients will take place at up to 9 clinical centers. Patients who meet all eligibility criteria will receive the AXIOS stent for up to 60 days indwell and 72 hour follow-up after stent removal.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cholecystitis, Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AXIOS(TM) Stent and Electrocautery Enhanced Delivery System

Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.

Group Type EXPERIMENTAL

AXIOS(TM) Stent and Electrocautery Enhanced Delivery System

Intervention Type DEVICE

Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AXIOS(TM) Stent and Electrocautery Enhanced Delivery System

Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient requiring intervention for the management of symptoms associated with acute cholecystitis
2. Patients referred for percutaneous drainage of the gallbladder who are not surgical candidates because of advanced age, anesthetic risk, significant co-morbidities and/or overall health
3. Eligible for endoscopic intervention
4. Acute Cholecystitis (AC) Grade I (mild) or II (moderate) per Tokyo guidelines:

* AC Grade I (mild) defined as acute cholecystitis in an otherwise healthy patient with mild local inflammatory changes and without organ dysfunction. Criteria for grade II or III not met.
* AC Grade II (moderate) defined by any one of the following characteristics

* Leukocytosis (\>18,000 cells per mm3)
* Palpable, tender mass in right upper quadrant
* Symptom duration \>72 hours
* Marked local inflammation (gangrenous or emphysematous cholecystitis, pericholecystic or hepatic abscess, biliary peritonitis)
5. Pre-drainage imaging confirms sufficient stone-free space to allow AXIOS™ stent deployment and complete flange expansion
6. 18 years of age or older
7. Willing and able to comply with the study procedures and patient or legally authorized representative (LAR) must provide written informed consent form (ICF) to participate in the study

Exclusion Criteria

1. AC Grade III (severe) per Tokyo guidelines defined by organ dysfunction in any one of the following systems:

* Cardiovascular - Hypotension requiring administration of ≥5μg/kg/min of dopamine or any dose of norepinephrine
* Neurologic - decreased level of consciousness
* Respiratory - PaO2/FiO2 \<300
* Renal - Oliguria and Creatinine \>2.0 mg/dl (\>177 μmol/liter)
* Hepatic - International normalized ratio \>1.5
* Hematologic - Platelet count \<100,000/mm3
2. Obvious signs on diagnostic imaging of perforated, extensive gangrenous or ischemic gallbladder
3. Hepatic abscess
4. Ascites
5. Patients with abnormal coagulation or who require ongoing complete anticoagulation
6. Bleeding diathesis
7. History of surgical treatment of acute cholecystitis (e.g. cholecystectomy)
8. Patients with a current percutaneous drainage
9. Patients with a history of percutaneous gallbladder drainage without AC free period following percutaneous drainage removal
10. Distance between gallbladder wall and duodenal or gastric wall \> 1cm by US (ultrasound) at the time of drainage
11. Patients with intervening gastric varices or vessels within a one centimeter radius of the device insertion location
12. Patients that have allergies or are sensitive to any of the device materials
13. Patients with contraindications to use of electrical devices
14. Pregnancy
15. Prisoners and other vulnerable populations

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No